Proceedings of the Ninth International Conference of Drug Regulatory Authorities (ICDRA) - Berlin, Germany 25-29 April 1999
(1999; 102 pages) View the PDF document
Table of Contents
Open this folder and view contentsOpening Ceremony
Open this folder and view contentsGood regulatory practice
Open this folder and view contentsGood certification practice
Open this folder and view contentsCounterfeit drugs: challenges and solutions
Open this folder and view contentsCurrent issues in regulation and quality
Close this folderInternational Conference on Harmonization: implementation and implications
View the documentIntroduction to the ICH
View the documentNon-ICH country perspective: Egypt
View the documentNon-ICH country perspective: Australia
View the documentRecommendations
Open this folder and view contentsDrug utilization studies
Open this folder and view contentsInternational Conference on Harmonization and the common technical document
Open this folder and view contentsKeynote address
Open this folder and view contentsGlobal and national efforts to reduce tobacco use
Open this folder and view contentsElectronic communication in the regulatory process
Open this folder and view contentsTransparency in monitoring the safety of medicines
Open this folder and view contentsPharmaceutical products for use in special groups
Open this folder and view contentsNeed for Bioequivalence
Open this folder and view contentsAntimicrobial resistance: battling the bugs
Open this folder and view contentsSafety issues of plasma-derived medicinal products
Open this folder and view contentsHerbal medicines
Open this folder and view contentsRegulation and access to essential drugs
View the documentParticipants
View the documentBack cover
 

Recommendations

1. Globalization of International Conference on Harmonization (ICH) guidelines should be further pursued as appropriate for Member States. WHO should continue to play an important role by taking into account the implications for non-ICH members.

2. WHO should explore the feasibility of integrating ICH products and WHO guidelines into a comprehensive set of guidelines.

3. Countries should take into consideration local factors in applying ICH guidelines.

4. ICH should give greater consideration to developing country needs through WHO particularly as this relates to the quality of all medical products including generic and over-the-counter (OTC) drugs. Mechanisms should be established to increase the balanced participation of developing countries in the consultative process of ICH. Non-ICH countries should actively seek opportunities to participate by reviewing documents under development and submitting comments early in the process, as appropriate.

5. ICH guidelines may be utilized by interested parties as a source of education and training.

6. Since ICH guidelines cover new products and many countries manufacture, register and use generic drugs, WHO is encouraged to continue work on guidelines on requirements for registration of generic drugs.

7. ICH updates should remain a subject for future ICDRAs and related WHO-sponsored regional meetings.

 

to previous section to next section
 

Last updated: April 24, 2012